A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Schistosoma mansoni Reinfection in Mice

Clarice Carvalho Alves 1, Neusa Araujo 2, Wilma Patricia de Oliveira Santos Bernardes 1, Mariana Moreira Mendes 1, Sergio Costa Oliveira 3,4 and Cristina Toscano Fonseca 1*

1 Laboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil, 2 Laboratório de Esquistossomose, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil, 3 Laboratório de Imunologia de doenças Infecciosas, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 4 Instituto Nacional de Ciências e Tecnologia em Doenças Tropicais, CNPq, MCT, Salvador, Brazil

The helminth Schistosoma mansoni is one of the main causes of human schistosomiasis, a health and economic concern in some of the world’s poorest countries. Current treatment regimens can lead to serious side effects and are not suitable for breastfeeding mothers. As such, efforts have been undertaken to develop a vaccine to prevent infection. Of these, Sm29 is a promising candidate that has been associated with resistance to infection/reinfection in humans and mice. Its ability to induce resistance to reinfection has also been recently demonstrated using a vaccine formulation containing Freund’s adjuvant. However, Freund’s adjuvant is unsuitable for use in human vaccines. We therefore evaluated the ability of Sm29 to induce protection against S. mansoni reinfection when formulated with either alum or MPLA as an adjuvant, both approved for human use. Our data demonstrate that, in contrast to Sm29 with MPLA, Sm29 with alum reduced parasite burden after reinfection compared to a control. We next investigated whether the immune response was involved in creating the differences between the protective (Sm29Alum) and non-protective (Sm29MPLA) vaccine formulations. We observed that both formulations induced a similar mixed-profile immune response, however, the Sm29 with alum formulation raised the levels of antibodies against Sm29. This suggests that there is an association between a reduction in worm burden and parasite-specific antibodies. In summary, our data show that Sm29 with an alum adjuvant can successfully protect against S. mansoni reinfection in mice, indicating a potentially effective vaccine formulation that could be applied in humans.

Keywords: Sm29, alum, MPLA-SM, Schistosoma mansoni, vaccine, reinfection
INTRODUCTION

Schistosomiasis is one of the most important global helminthic infection, in terms of disability-adjusted life years (DALYs) (1, 2). Due to large effects on public health and productivity, a considerable amount of effort has been applied to finding candidates that could serve as an anti-schistosomiasis vaccine (3). One such promising vaccine candidate is the Schistosoma mansoni tegument protein Sm29. In areas endemic for schistosomiasis, high levels of circulating anti-Sm29 IgG1 and IgG3 have been associated with resistance to infection (4). Sm29 has also been tested using several experimental immunization protocols, consistently showing an ability to reduce worm burden. The first study that evaluated Sm29 with an experimental immunization protocol was published in 2008 and demonstrated a significant reduction in the number of adult worms after challenge (5). There was also an accompanying immune response that was defined by the production of high levels of IFN-γ and IgG1. Later, the protein was tested in combination with SmTSP-2 as a recombinant chimeric protein in order to more effectively potentiate the isolated antigens (6). Immunization with this chimeric protein also resulted in a significant reduction in parasite burden. In this case however, protection associated with high levels of specific IgG1 and IgG2a antibodies and a Th1 polarized immune profile, with significant production of IFN-γ and TNF-α. Finally, another chimeric protein consisting of Sm29 and Sm14 was also tested, showing protection against S. mansoni that was accompanied by significant production of IgG1 antibodies (7).

To further evaluate Sm29 as a vaccine candidate, we have recently tested this antigen in mice that were previously infected with S. mansoni and treated with praziquantel (8). Such pre-sensitization more accurately mimics the situation found in endemic areas in which the population is constantly being reinfected with the parasite. This study demonstrated that Sm29 with Freund’s adjuvant provided protection against reinfection in these pre-sensitized animals (26–48%). Vaccination also induced an increase in overall antibody levels and a mixed cellular immune response (8). However, Freund’s adjuvant is not recommended for use in humans due to high toxicity. Alternatively, alum adjuvants are widely used in human vaccine formulations (9), although only recently its mechanism of action began to be elucidated. In 2008, two groups demonstrated that alum activates inflammasomes through a NLRP3 dependent-pathway (10, 11). Alum induces tissue damage that leads to uric acid release, enhancing the uptake of antigens by antigen presenting cells (APCs) (12). However, a more recent study has suggested that the effects of alum on the adaptive response may not involve NLRP3, but rather IL-2 production by dendritic cells (DCs). In the study, IL-2 released by DCs was dependent on phagocytosis, Syk, and NFAT activation. In the absence of IL-2-producing DCs, alum inoculation resulted in decreased proliferation of CD4+ T cells and decreased antibody production (13). Nevertheless, alum induces a Th2 type of immune response, irrespective of the exact signaling pathways involved in alum-mediated activation (12, 14, 15). In addition to alum, monophosphoryl lipid A (MPLA) is also used as an adjuvant in human vaccines (16). It is a derivate of lipid A from LPS that lacks toxicity but remains immunogenic (17, 18). The adjuvant is an agonist of TLR4, activating APCs through a TRIF-dependent signaling pathway (19). APC activation induced by MPLA results in increased production of TNF-α, IL-10, and IL-12 by APCs (20). MPLA as an adjuvant has been demonstrated to activate both the humoral and cellular arms of the immune response (21, 22).

As Freund’s adjuvant is not licensed to be used in human vaccines, this study tested whether recombinant Sm29 antigen with MPLA or alum as an adjuvant could be effective in an animal model of S. mansoni reinfection. In addition, the immunological profiles induced by the vaccines were assessed. Our data show that immunization with Sm29 and alum was indeed able to induce partial protection against reinfection, reducing parasite burden by 29–37% in immunized mice. The Sm29 with MPLA formulation was unable to induce a reduction in worm burden, providing a powerful tool to understand why the Sm29 with alum formulation was effective. Further study comparing the two formulations suggested antibody production was important to the protective effect and higher antibody levels were observed in Sm29 and alum immunized animals. Although further investigation concerning the relationship between protection and antibody production is required, our data indicate that a vaccination formulation containing Sm29 and alum could potentially be used to control human schistosomiasis.

MATERIALS AND METHODS

Mice and Parasites

Female BALB/c mice aged 6–8 weeks were obtained from the Centro de Pesquisas René Rachou (CPqRR)-FIOCRUZ (Fundação Oswaldo Cruz) animal facility, Brazil. LE strain S. mansoni cercariae were obtained by exposing infected Biomphalaria glabrata snails to light for 1–2 h to induce shedding. This S. mansoni strain is routinely maintained at the Lobato Paraense, CPqRR. The Ethics Committee of Animal Use (CEUA) of FIOCRUZ approved the protocols involving animals in this study under license number LW12/12.

Antigen Preparation

Recombinant Sm29 (rSm29) was produced and purified as previously described (4). Briefly, the protein was expressed in Escherichia coli BL21 bacteria carrying a pET21 expression vector containing the Sm29 cDNA. Expression was induced using 1 mM IPTG. After bacterial lysis, rSm29 was purified by affinity chromatography on nickel columns. The protein was then dialyzed against phosphate buffered saline (PBS) pH 7.2 and its concentration determined using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, United States).

Vaccination Protocol

Before immunization, mice were sensitized using a prior S. mansoni infection with approximately 30 LE-strain cercariae. Forty-five days after infection, mice were treated with two doses of 800 mg/Kg Praziquantel as previously described (8). Fifteen days after treatment, mice were immunized (10
animals/group) with rSm29 (25 µg/animal) plus alum adjuvant -Alhydrogel (InvivoGen, San Diego, CA, United States) (1 mg/mouse/dose) or MPLA-SM VacCiGrade (InvivoGen, San Diego, CA, United States) adjuvant (10 µg/mouse/dose). The control groups were inoculated with saline and either alum or MPLA-SM VacCiGrade, respectively. Mice received three doses of each vaccine over the 15-d interval regimen, applied subcutaneously in the nape of the neck.

Challenge Infection and Worm Burden Recovery

Animals were challenged by percutaneous infection with 100 cercariae (LE strain) 30 days after the final vaccine booster. Mice abdominal skin was shaved and exposed for 1 h to the cercariae. Fifty days after infection, adult worms were recovered from the portal veins as described by Pellegrino and Siqueira (23). The levels of protection were calculated as previously described (8). Fragments from the liver and intestine from control and experimental groups were collected after perfusion. These organs were weighted, digested in a solution of 10% KOH. The eggs were obtained and it number determined as previously described (8).

Antibody Assessment

The sera from the mice of each vaccinated group were obtained 15 days after each immunization dose. Enzyme-linked immunosorbent assays (ELISAs) were performed using the sera to evaluate the production of IgG, IgG1, IgG2a, and IgE antibodies specific to rSm29. Briefly, MaxiSorp 96-well microtiter plates (Nunc, Rochester, NY, United States) were coated with rSm29 at a concentration of 5 µg/mL (for IgG, IgG1, and IgG2a), or 1 µg/mL (for IgE) in carbonate-bicarbonate buffer (pH 9.6). These were left overnight at 4°C and were then blocked with 300 µL/well of phosphate-buffered saline (pH 7.2) with 0.05% Tween-20 (PBST) and 3% fetal bovine serum (FBS; GIBCO, Gaithersburg, MD, United States), for 2 h at 25°C (for IgG, IgG1, and IgG2a), or PBST plus 3% skim milk overnight at 4°C (for IgE). One hundred microliters of each serum sample was added for 30 min. The plates were incubated with peroxidase-conjugated anti-mouse IgG (1:10,000), IgG1, (1:10,000), or IgG2a (1:8,000) (Southern Biotech, Birmingham, AL, United States), for 1 h at 25°C. For the IgE measurements, an anti-mouse biotin IgE (BD Biosciences, Franklin Lakes, NJ, United States) diluted to 1:250 was used. After incubation for 1 h at 25°C, an avidin conjugated to peroxidase (1:250) was added for 30 min. For all ELISAs, a TMB incubation was used to visualize antibody concentrations and was stopped with 5% sulfuric acid. Finally, the plates were read at 450 nm using an ELISA plate reader (Bio-Rad, Hercules, CA, United States). Endpoint antibody titers were determined using pool of sera samples from each group and a serial dilution range from 1:20 to 1:1,310,720.

Cellular Immune Response and Immunophenotypic Analysis

To assess cytokine production, the spleens from at least five mice per group were collected 7 days after the final immunization dose. Red blood cells were lysed using ACK lysis buffer and the remaining splenic cells were washed twice with pyrogenic saline before being adjusted to 1 x 10⁶ cells/well. Cells were cultured in 5% CO₂ at 37°C without stimulation (negative control), stimulated with anti-CD3 (1 µg/mL) as a positive control, or rSm29 (25 µg/mL). Culture supernatants were collected 24 or 72 h post stimulation to access the levels of IL-2 (24 h), IL-4 (24 h), IL-6 (24 h), IL-10 (72 h), IL-17 (72 h), IFN-γ (72 h), and TNF-α (24 h). Cytokine measurements were performed using an anti-mouse Th1/Th2/Th17 Cytometric Bead Array (CBA) Kit (BD Biosciences, Franklin Lakes, NJ, United States) following the manufacturer's protocol. The beads were quantified using a FACScalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, United States) and the data analyzed using FCAP Array Software (BD Biosciences, Franklin Lakes, NJ, United States).

The proportions of CD4⁺ lymphocytes producing IL-4, IFN-γ, or IL-10 were also evaluated via intracytoplasmic staining. Cells were initially processed as previously described, but were adjusted to 0.5 x 10⁶ cells per well and cultured for 18 h in the absence of polyclonal or antigen specific stimulation. To prevent cytokine secretion in the last 4 h, brefeldin A (1 µg/mL) was added to the culture. The cells were then blocked with either anti-CD16 or CD32 mAbs (clone 2.4G2; BD Biosciences, Franklin Lakes, NJ, United States). Surface molecules were stained by incubating the cells for 15 min with anti-CD4 conjugated to FITC (clone GKL1.5; BD Biosciences, Franklin Lakes, NJ, United States) and anti-CD3 conjugated to biotin (clone 500A2; BD Biosciences, Franklin Lakes, NJ, United States). The cells were then washed with PBS (0.15 M) containing BSA (0.5%) and NaN₃ (2 mM). Streptavidin PE-CF594 (BD Biosciences, Franklin Lakes, NJ, United States) was then added. The cells were left for an additional 15 min at 4°C, washed with PBS and then fixed and permeabilized using Cytofix/Cytoperm fixation/permeabilization solution (BD Biosciences, Franklin Lakes, NJ, United States) for 20 min at 4°C. The cells were next incubated for 30 min with specific to anti-IL-4 conjugated to PE (clone 1B11; BD Biosciences, Franklin Lakes, NJ, United States), anti-IFN-γ conjugated to eFluo450 (clone XMGl2.3; eBioscience, San Diego, CA, United States), and anti-IL-10 conjugated to APC (clone JESS-16E3; BD Biosciences, Franklin Lakes, NJ, United States) monoclonal antibodies. They were then washed with the same Cytofix/Cytoperm buffer (BD Biosciences, Franklin Lakes, NJ, United States) and sorted using an LSRFortessa BD flow cytometer (BD Biosciences, Franklin Lakes, NJ, United States). For the ex vivo analyses, splenocytes were incubated with CD16/CD32 and then anti-CD3 (clone 500A2; BD Biosciences, Franklin Lakes, NJ, USA), anti-CD4 (clone GKL1.5; BD Biosciences, Franklin Lakes, NJ, United States), anti-CD11c (clone N418; eBioscience, San Diego, CA, United States), or anti-F4/80 conjugated to FITC (clone BM8; eBioscience, San Diego, CA, United States); anti-CD86 conjugated to PE (Accurate Chemical and Scientific Corporation, Westbury, NY, United States); anti-CD3 (clone 500A2; BD Biosciences, Franklin Lakes, NJ, United States), anti-CD27 (clone LG.7F9; Bioscience, San Diego, CA, United States), anti-F4/80 (clone BM8; Bioscience, San Diego, CA, United States), or anti-CD40 conjugated to biotin (eBioscience, clone 1C10);
anti-CD62L conjugated to APC-Cy7 (clone MEL-14; BD Biosciences, Franklin Lakes, NJ, United States); anti-CD19 (clone 1D3; BD Biosciences, Franklin Lakes, NJ, United States), anti-CD127 (clone A7R34; BD Biosciences, Franklin Lakes, NJ, United States), or anti-CD11b conjugated to PE-Cy7 (clone M1/70; BD Biosciences, Franklin Lakes, NJ, United States); anti-I-A/I-E conjugated to Alexa 647 (clone M5/114.15.2; BD Biosciences, Franklin Lakes, NJ, United States); and anti-CD44 conjugated to Alexa 700 (clone IM7; eBioscience, San Diego, CA, United States) monoclonal antibodies. Then, cells were washed and incubated for 20 min with streptavidin APC-Cy7 or PeCF594. Finally, cells were fixed with 2% formaldehyde solution and acquired using an LSRFortessa (BD Biosciences, Franklin Lakes, NJ, United States). The data were analyzed using FlowJo software 7.6.3 (FlowJo LLC, Ashland, OR, United States). During analysis, sample acquisition that presented reduced number of acquired events, interruption of flow during acquisition or excessive number of doublets were excluded from the analysis. The staining panel used for each cell characterization is described in Supplementary Table 1.

Statistical Analysis
Data normality was tested using D’Agostino-Pearson omnibus tests. Based on a Grubbs’ test, outliers were identified and eliminated. Statistical analyses were performed using ANOVA and Tukey’s multiple comparison for the cytokine measurements and ex vivo analyses, or Student’s t-tests for the parasitological analyses and antibody measurements. All calculations were performed using GraphPad Prism 7.02 (Graph-Pad Software, La Jolla, CA, United States).

RESULTS
rSm29 Formulated With Alum Induces Partial Protection Against S. mansoni Infection in Pre-sensitized Mice
Animals immunized with the vaccine formulation containing alum as an adjuvant (Sm29Alum) showed a protection level between 29 and 37%. A significant reduction in worm burden (25 ± 8; 26 ± 13 and 27 ± 10-trials 1, 2 and 3, respectively) after S. mansoni challenge was observed in these animals in comparison to PBS alum group (35 ± 9; 41 ± 8 and 38 ± 6-trials 1, 2, and 3, respectively). In contrast, immunization with the MPLA adjuvant (Sm29MPLA) did not confer any protection against reinfection challenge (Table 1). Sm29MPLA group presented 26 ± 11; 34 ± 15 and 33 ± 10 mean worm burdens and PBS/MPLA group presented 27 ± 12; 38 ± 16 and 31 ± 8 mean worm burdens after the first, second and third trials, respectively. In addition to the determination of the number of worms recovered, the number of parasite eggs trapped in the liver or crossing the intestine wall was determined. Agreeing with the significative reduction of the parasite burden, significantly fewer parasite eggs were observed in the liver

### Table 1: Worm recovery and protection level in Sm29 immunized groups.

|                | Male Mean ± SD | Female Mean ± SD | Total Mean ± SD | % of protection<sup>b</sup> | Egg/gram of liver Mean ± SD | % of reduction<sup>b</sup> | Egg/gram of intestine Mean ± SD | % of reduction<sup>b</sup> |
|----------------|----------------|------------------|-----------------|-----------------------------|----------------------------|-----------------------------|-------------------------------|-----------------------------|
| **TRIAL 1<sup>a</sup>** |                |                  |                 |                             |                            |                             |                               |                             |
| Challenge control |                |                  |                 |                             |                            |                             |                               |                             |
| ALUM           | 17 ± 5         | 18 ± 4           | 35 ± 9          |                             | ND                         | ND                          |                               |                             |
| Sm29 ALUM      | 12 ± 4         | 12 ± 4           | 25 ± 8          | 29% (p = 0.03)              | ND                         | ND                          |                               |                             |
| MPLA           | 13 ± 6         | 15 ± 7           | 27 ± 12         |                             | ND                         | ND                          |                               |                             |
| Sm29 MPLA      | 13 ± 5         | 13 ± 6           | 26 ± 11         | 4% (NS)                     | ND                         | ND                          |                               |                             |
| **TRIAL 2<sup>a</sup>** |                |                  |                 |                             |                            |                             |                               |                             |
| Challenge control |                |                  |                 |                             |                            |                             |                               |                             |
| ALUM           | 21 ± 4         | 20 ± 4           | 41 ± 8          |                             | 14241 ± 2695               | 23% (p = 0.04)              | 9727 ± 5248                  | (NS)                        |
| Sm29 ALUM      | 15 ± 7         | 15 ± 9           | 26 ± 13         | 37% (p = 0.02)              | 11004 ± 2776              | 23% (p = 0.04)              | 9727 ± 5248                  | (NS)                        |
| MPLA           | 18 ± 8         | 20 ± 9           | 38 ± 16         |                             | 10288 ± 2077              | 10400 ± 8712               | 9860 ± 4813                  | 5% (NS)                     |
| Sm29 MPLA      | 18 ± 7         | 17 ± 8           | 34 ± 15         | 11% (NS)                    | 13665 ± 3391             | 9860 ± 4813                  | 9860 ± 4813                  | 5% (NS)                     |
| **TRIAL 3<sup>a</sup>** |                |                  |                 |                             |                            |                             |                               |                             |
| Challenge control |                |                  |                 |                             |                            |                             |                               |                             |
| ALUM           | 20 ± 5         | 17 ± 4           | 38 ± 6          |                             | 43285 ± 21394            | 8265 ± 1536                 | 7594 ± 4287                  | 8% (NS)                     |
| Sm29 ALUM      | 15 ± 5         | 13 ± 5           | 27 ± 10         | 29% (p = 0.04)              | 22554 ± 5726            | 7594 ± 4287                  | 7594 ± 4287                  | 8% (NS)                     |
| MPLA           | 16 ± 5         | 15 ± 3           | 31 ± 8          |                             | 58346 ± 28976           | 7594 ± 4287                  | 7594 ± 4287                  | 8% (NS)                     |
| Sm29 MPLA      | 14 ± 6         | 15 ± 7           | 33 ± 10         | (NS)                        | 44069 ± 24010           | 12042 ± 5743                 | 12042 ± 5743                 | (NS)                        |

<sup>a</sup>For each vaccinated group: n = 10 mice.

<sup>b</sup>Comparison between total burden recovered from Sm29 ALUM or MPLA group and ALUM or MPLA control group.

NS, not significant.

ND, not determined.
of animals immunized with Sm29alum. But, any significant differences in the number of eggs per gram of intestine were observed between experimental and control groups, regardless the vaccine formulation.

**Alum and MPLA Adjuvants Induce Similar APC Activation Profiles**

To evaluate how the adjuvants impact APC activation, we analyzed CD86 expression by DCs, and MHC II and CD40 expression by macrophages, isolated from the spleens of immunized, adjuvant control and infected and treated (IT) animals 7 d after the last immunization dose. No differences were found in the expression of CD86 on DCs, or in MHC II and CD40 expression on macrophages, between the groups (Figure 1). Although Alum Sm29 trigger a protective immune response, nor alum, neither MPLA presented an additional effect in activating DC and macrophages in mice that have been sensitized by a previous *S. mansoni* infection, suggesting that alum-induced protective mechanism is acting further upstream of the immune response.

**Both Sm29Alum and Sm29MPLA Vaccine Formulations Induce a Mixed Th1/Th2/Th17 Type Immune Response**

Next, the cellular immune responses triggered by Sm29Alum, Sm29MPLA immunization and their respective adjuvant controls were assessed to understand the cytokine profiles involved in the protective (Sm29Alum) and non-protective vaccine formulation (Sm29MPLA). The impact of APC activation in T cell differentiation was also evaluated by

![Graphs showing APC activation](image-url)

**FIGURE 1 | Activation status of dendritic cells (DC) and macrophages.** Spleen from 5 to 6 animals was obtained for each group. Dendritic cells and macrophages were labeled to evaluate the expression of activation markers. For dendritic cells analysis, CD11c+ and MHC+ double positive cells were selected and the mean fluorescence intensity (MFI) of CD86 was determined (A). For macrophages, F4/80 and CD11b double positive cells were selected and the mean fluorescence intensity of MHCII and CD40 were evaluated (C). Data of CD86 MFI in dendritic cells (B), MHCII MFI (D) and CD40 MFI (E) in macrophages from animals of MPLA (closed triangles), Sm29 MPLA (closed circles), Alum (open triangles), Sm29 Alum (open circles) and infected/treated (gray circles) groups are represented on graphics. Results are representative of one from two independent experiments.
intracellular staining using flow cytometry. We found that similar proportions of CD4+ cells producing IL-4, IFN-γ, and IL-10 were observed in the spleens of mice immunized with Sm29/MPLA or Sm29/Alum and their adjuvant control groups (Figure 2). Also, no differences in the proportion of CD4+ cells producing cytokine was observed in infected and treated group in comparison to other groups. Regarding cytokine production by spleen cells, Sm29 in vitro stimulation led to an increased production of TNF-α and IL-6 in all groups. IL-10 and IFN-γ production was also increased in all groups, except MPLA (Figure 3). Sm29/MPLA immunization significantly increased IFN-γ production in comparison to MPLA inoculated animals (Figure 3E). Significant IL-17 production was only observed in the groups of animals that received Sm29 immunization. IL-6 levels were significantly higher in Sm29/MPLA group in comparison to Sm29/Alum and infected and treated groups (Figures 3B,D). Cytokine production under antigen specific recall was expected in the adjuvant control groups and in infected and treated mice (IT), since those animals were sensitized by a previous infection. However, as rSm29 was produced in bacteria, endotoxin contamination might also have contributed to the production of LPS-induced cytokines in stimulated cells. IL-4 and IL-2 levels were below CBA detection levels and could not be determined. Together, these results indicate that Sm29 immunization in association with Alum or MPLA does not significantly alter the immune profile induced by a previous infection with *S. mansoni*, and induces a Th1/Th2/Th17 mixed type of immune response.

**Mice Immunization With Sm29 Decreases the Percentage of B Cells in Spleen, but Fails to Increase the Percentage of Memory Cells**

The percentage of B and T memory cells was determined as demonstrated in Figures 4A, 5A. A decrease in the percentage and absolute number of B cells in spleen was observed in mice immunized with Sm29 MPLA in comparison to Sm29 Alum and IT groups (Figures 4B,D). Significant decrease in the proportions and number of memory B cells, characterized as CD3−CD19+CD27+ cells was observed in all groups in comparison to IT group (Figures 4C,E). Nevertheless, any difference in the proportions of CD4+ central memory T cells (CD3+CD4+CD44hiCD127+CD62L+) or effector memory T cells (CD3+CD4+CD44hiCD127+CD62L−) was observed between groups (Figures 5B,C). Although a significant reduction in the number of CD4+ central memory cells was observed in Sm29 immunized mice in comparison to IT group (Figure 5D). No significant reduction in the number of CD4+ effector memory cells was observed (Figure 5E).

**The Sm29Alum Vaccine Formulation Promotes Higher Titers of Anti-Sm29 Antibodies**

To more fully establish the role of antibody production in protection against *S. mansoni* reinfection, we examined the humoral response in more detail for Sm29Alum and...
FIGURE 3 | Cytokine production by spleen cells culture of immunized mice. Spleen from animals of MPLA (n = 11); Sm29 MPLA (n = 14); Alum (n = 11), Sm29 Alum (n = 15) and Infected and treated (n = 11) groups were obtained. Spleen cells cultured with (black bars) or without (open bars) rSm29 (25 µg/mL) stimulation was assessed to determine cytokine production. The levels of TNF-a (A), IL-6 (B), IL-10 (C), IL-17 (D), and IFN-γ (E) were measured by the CBA Th1/Th2/Th17 Kit. Statistically significant differences are denoted on the graphics. Bars represents the mean ± SD values of three independent experiments.

DISCUSSION

The Sm29 tegument protein from *S. mansoni* (5) has been considered a promising candidate that could serve as a vaccine against schistosomiasis. This is primarily due to its ability to reduce parasite burden across a range of vaccine strategies and formulations (5, 24, 25). The ability of Sm29 to induce protection against reinfection has recently been described, reinforcing its potential as a vaccine candidate (8). Here, we have built on this initial study that used Freund’s adjuvant to induce protective immunity by testing vaccines containing Sm29 with two adjuvants approved for use in humans, alum and MPLA. Our
FIGURE 4 | Frequency of B memory cells in immunized mice. Spleen from 5 to 6 animals was obtained for each group to determine the frequency of B memory cells. Data analysis was carried out as demonstrated (A): within singlet cells/lymphocyte population, CD19<sup>+</sup> and CD3<sup>-</sup> cells were selected and the percentage of B cells was determined. B memory cells were assessed by determining CD19<sup>+</sup>CD27<sup>+</sup> cell frequency. Data represents percentage and number of B cells (B,D) and B memory cells (C,E) in animals from MPLA (closed triangles), Sm29 MPLA (closed circles), Alum (open triangles), Sm29 Alum (open circles) and infected/treated (gray circles) groups. Statistically significant differences are denoted on the graphics. Results are representative of one from two independent experiments.

A study has shown that the Sm29Alum formulation elicited partial protection, whereas Sm29MPLA did not. This has provided a valuable tool to investigate the immune responses associated with successful vaccine protection against *S. mansoni*.

Adjuvants are important components of vaccine formulation and are responsible for inducing local inflammation that favors APC activation and differentiation (26). However, alum and MPLA belong to different classes of adjuvants, with MPLA acting...
as a TLR4 agonist (19). Alum is not recognized by any known innate sensor and instead leads to tissue damage and the release of uric acid that is detected by cells of the innate immune system (12). Despite using different mechanisms that can be either direct or indirect, these adjuvants activate innate cells, including professional antigen presenting cells, linking the innate response to adaptive response. This is essential for immunity induced by vaccines (10–13). Under our immunization protocol, both alum and MPLA showed no additional effect in activating DCs and macrophages, since the level of expression of activation markers in both cell types are similar to the ones observed in not immunized infected and treated mice. In addition to a role in activating APCs, the induction of a cytokine profile capable of eliciting protective effector function is also critical. Our cytokine measurements using the supernatants of cultured splenocytes isolated from animals of each groups, demonstrates a significant production of IL-6, IL-10 and TNF-a in response to rSm29 stimulation in all groups. Endotoxin contamination in the rSm29 might have contributed to increase the production of these cytokines in vitro. But it was previously demonstrated that Sm29 itself stimulate the production of LPS-induced cytokines, in TLR4KO mice (5). In addition, no differences were found in the proportions of IFN-γ, IL-4, or IL-10 producing CD4+ T cells. But Sm29 immunization regardless the adjuvant used induces a significant production of IL-17 under specific stimulation. These observations demonstrate that, under a context of prior sensitization with the parasite, both formulations induce a mixed Th1/Th2/Th17 immune response. Analysis of the IgG1/IgG2a ratio corroborates this observation. It has previously been shown that Sm29 immunization of naive animals induces a Th1-type immune response characterized by increased IFN-γ production (5, 24). However, it was recently demonstrated that there is also
production of Th2 cytokine markers by spleen cells in response to rSm29 after challenge (25). These discrepancies may be due to the fact that we used BALB/c mice instead of C57BL/6 mice to test the protection levels induced by vaccination. BALB/c mice produce higher levels of IL-13 and IL-4 than C57BL/6 mice in response to parasite soluble eggs-antigens stimulation after S. mansoni infection and reinfection (27). Is also worth mention that although we didn’t measured cytokine after reinfection, in our model mice were primed with a S. mansoni infection before immunization. Therefore, the experimental model used in our study appears more prone to a Th2-type response, even before immunization.

In our study we have observed a decreased number of B cell in spleen from mice immunized with Sm29 MPLA, while the Sm29 alum immunization didn’t change the proportion and number of B cells in comparison with mice from the infected and treated group. However, immunization significantly reduced the number of B memory cells. Alum has been described as an adjuvant that activates Th follicular cells which is important to memory B cells and long-lived plasma cells differentiation (28). Once we had not observed increased percentage of memory B cells in Sm29 alum immunized animals, B cells in the spleen of immunized mice might be differentiating into plasma cells rather than into memory cells. Therefore, the protective effect mediated by Sm29Alum is likely to be linked to antibody production rather than memory function. Our data have also revealed the importance of antibody production in eliciting effective protection. Several studies have also demonstrated that antibodies play a key role in the protection induced by other schistosome vaccine candidates (29–31). In particular, our results demonstrate that the protective vaccine formulation (Sm29Alum) induced increased production of antibodies specific to Sm29, with endpoint titers at least twice as high as those observed in the non-protective formulation (Sm29MPLA). However, it is important to state that although Sm29 is one of the major antigen targets in the sera of mice, rats, and humans infected with S. mansoni (32), high production of anti-Sm29 antibodies does not necessarily correlate with resistance to infection. Despite this, isotype specific antibody responses have been associated with resistance in humans. Individuals naturally resistant to S. mansoni infection and reinfection produce high levels of Sm29-specific IgG1, or IgG1 and IgG4, respectively (4, 33). We also observed higher endpoint titers of Sm29-specific IgG1 (that correlate with the human IgG4 isotypes) and IgE antibodies in the mice that received the protective Sm29Alum formulation. A previous study using Sm29 formulated with Freund’s adjuvant in mice sensitized by prior infection also led to increased production of specific anti-Sm29 antibodies (8). In the study, three doses of vaccine were necessary to induce protection, with the levels of specific IgG1 and IgG2a increasing with each boost and the highest titers reached after the third dose (8). Together, these data suggest that antibodies are
associated with the protective immunity shown by Sm29Alum against S. mansoni reinfection in mice. Despite its ability to induce a protective immune response in mice, Sm29 alum immunization also induces significant production of specific IgE. IgE against vaccine candidates is a safety concern when developing vaccine formulations. IgE against vaccine candidates might induce allergic reactions in vaccinees, as the systemic urticarial reaction observed in the Na-ASP2 hookworm vaccine clinical trial (34). Therefore, Sm29 alum allergenicity should be tested before moving for clinical trials.

No difference in the percentage of B memory cells was observed between the immunized groups. We also did not observe any differences in the proportions of CD4+ T memory cells between the Sm29Alum and Sm29MPLA groups. Previous human studies in S. haematobium endemic areas have demonstrated that an increase in the proportion of CD4+ T memory cells associates with age and resistance to reinfection (35). However, in our study, we did not observe any association between T or B memory cells and the protective response, but increased numbers of B and T memory cells are observed in infected and treated group in comparison to Sm29 immunized animals, indicating that memory cells reflect previous exposure to the parasite rather than protection.

The use of the mouse model in the study of vaccine formulations against schistosomiasis was criticized in a review published recently (36), due to physiological characteristics of the mouse that might reduce parasite migration and maturation in a non-specific way. However, is worth mention that in our model, the control group (adjuvant group) received the same treatment as the experimental group, except for the absence of the antigen in the vaccine formulation. Therefore, the partial protection observed in Sm29Alum experimental group can only be attributed to the acquired immune response triggered by the vaccine. Mice also represent a valuable animal model to explore the immune mechanism associated with protection, in contrast to other animal models a huge amount of tools, as monoclonal antibodies, knockout and conditional knockout mice are available. The knowledge generated using mice models are useful to screen vaccine candidates and rationally design a vaccine formulation to be used in humans. However, once promising antigen have been identified and the mechanisms of protective immunity have been clarified, vaccine formulations should also be evaluated in other animal models before moving forward to clinical trials.

In conclusion, our study has shown that a vaccine formulation containing Sm29 and alum is able to confer protection against S. mansoni reinfection in mice. Our further functional investigation suggests that this may be due to an association between Sm29-specific antibodies and protective immunity, although further work to clarify this relationship is required. Nevertheless, our data indicate that a vaccination formulation containing Sm29 and alum could contribute to the control of human schistosomiasis and should be examined further.

AUTHOR CONTRIBUTIONS

CA, NA, WB, and MM participated in the experiments. CA, SO, and CF performed data analysis. CA and CF designed the study.

FUNDING

This work was supported by CNPq/Programa Estratégico de Apoio à Pesquisa em Saúde—Papes VI/Fiocruz—grant number: 407702/2012-1 (PI: CTF); CNPq/Programa de Excelência em Pesquisa—Proep/CPqRR grant number: 402010/2012-4 (PI: CTF), Fapemig/Programa de Pesquisa para o SUS-PPSU: APQ-003478-13 (PI: CTF), and Capes/Programa Brasil Sem Miséria (CA-Fellowship).

ACKNOWLEDGMENTS

We thank the program for technological Development in tools for Health-PDTIS FIOCRUZ for use of it facilities.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02488/full#supplementary-material

REFERENCES

1. Hotez PJ, Strych U, Lustigman S, Bottazzi ME. Human helminthic vaccines: rationale and challenges. Vaccine (2016) 34:3549–55. doi: 10.1016/j.vaccine.2016.03.112
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 386:743–800. doi: 10.1016/S0140-6736(15)60692-4
3. Fonseca CT, Oliveira SC, Alves CC. Eliminating schistosomes through vaccination: what are the best immune weapons? Front Immunol. (2015) 6:95. doi: 10.3389/fimmu.2015.00095
4. Cardoso FC, Pacifico RN, Mortara RA, Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.
Alves et al. rSm29/Alum Protects Mice Against Schistosomiasis

Clin Exp Immunol. (2006) 144:382–91. doi: 10.1111/j.1365-2249.2006.03081.x

5. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, et al. *Schistosoma mansoni* tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis. (2009) 3:e308. doi: 10.1371/journal.pntd.0000308

6. Pinheiro CS, Ribeiro AP, Cardoso FC, Martins VP, Figueiredo BC, Assis NR, et al. A multivalent chimeric vaccine composed of *Schistosoma mansoni* SmTSP-2 and Sm29 was able to induce protection against infection in mice. Parasite Immunol. (2014) 36:303–12. doi: 10.1111/pim.12118

7. Ewaisha RE, Bahey-El Din M, Mossallam SF, Amer EI, Aboushehbi HM, Khalil AM. Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental *Schistosoma mansoni* infection. Exp Parasitol. (2014) 145:51–60. doi: 10.1016/j.exppara.2014.07.010

8. Alves CC, Araujo N, dos Santos VC, Couto FB, Assis NR, Morais SB, et al. Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a *Schistosoma mansoni* infection. PLoS Negl Trop Dis. (2015) 9:e0003537. doi: 10.1371/journal.pntd.0003537

9. Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine (2002) 20(Suppl. 3):S24–33. doi: 10.1016/s0264-410x(02)00168-8

10. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role of monophosphoryl lipid A. *Infect Immun.* (2003) 71:2498–507. doi: 10.1128/IAI.00022-11

11. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. *J Immunol.* (2008) 181:17–21. doi: 10.4049/jimmunol.181.1.17

12. Kool M, Soulé T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Adjuvant boosting adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med.* (2008) 205:869–82. doi: 10.1084/jem.20071087

13. Khameneh HJ, Ho AW, Spreatco R, Derks H, Quek HQ, Mortellaro A. Khameneh HJ, Ho AW, Spreatco R, Derks H, Quek HQ, Mortellaro A. Rationally designed TLR4 ligands for vaccine adjuvant discovery. *Parasite Immunol.* (2014) 36:107–11. doi: 10.1111/pim.12091

14. Noonan W, Bourke CD, Appleby LJ, Rujeni N, Lantz O, Trottein F, et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. *J Allergy Clin Immunol.* (2016) 138:782–8.e1. doi: 10.1016/j.jaci.2016.03.004

15. Breuer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. Role of antibodies in Sm-p80-mediated protection against *Schistosoma mansoni* challenge infection in murine and nonhuman primate models. *Vaccine* (2011) 29:2262–71. doi: 10.1016/j.vaccine.2011.01.040

16. Smith G, Wynn TA, Kahnberg MC, Hiener S, Caspar P, James S, et al. Optimal vaccination against *Schistosoma mansoni* requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms. *J Immunol.* (1999) 162:345–51.

17. Kato M, Soullé T, van Nimwegen M, Willart MA, Muskens F, Jung S, et al. Adjuvant boosting adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med.* (2008) 205:869–82. doi: 10.1084/jem.20071087

18. Khameneh HJ, Ho AW, Spreatco R, Derks H, Quek HQ, Mortellaro A. The Syk-NFAT-IL-2 pathway in dendritic cells is required for optimal sterile immunity elicited by alum adjuvants. *J Immunol.* (2017) 198:196–204. doi: 10.4049/jimmunol.1600420

19. Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. *Cell Immunol.* (1989) 121:134–45. doi: 10.1016/0008-4979(89)90011-7

20. Breuer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant but continues to induce T helper 2 cytokine production. *Eur J Immunol.* (1996) 26:2062–6. doi: 10.1002/eji.1830260915

21. Greggs KA, Harberts E, Gardner FM, Pelletier MR, Cayette C, Yu L, et al. Rationally designed TLR4 ligands for vaccine adjuvant discovery. *mBio* (2017) 8:e00492–17. doi: 10.1128/mBio.e00492-17

22. Qureshi N, Takayama K, Ribl E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. *J Biol Chem.* (1982) 257:11808–15.

23. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. The Toll-like receptor 4 agonist monophosphoryl lipid A augments innate host resistance to systemic bacterial infection. *Infect Immun.* (2011) 79:5576–87. doi: 10.1128/IAI.00222-11

24. Mata-Haro V, Céci C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophospholipid A as a TRIF-activated agonist of TLR4. *Science* (2007) 316:1628–32. doi: 10.1126/science.1138963

25. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophospholipid A. *Infect Immun.* (2003) 71:2498–507. doi: 10.1128/IAI.71.5.2498-2507.2003

26. Todoroff J, Lemaire MM, Filler C, Jurion F, Renault JC, Huysgen K, et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. *PLoS ONE* (2013) 8:e63344. doi: 10.1371/journal.pone.0063344

27. Hu X, Liu R, Zhu N. Enhancement of humoral and cellular immune responses by monophospholipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice. *Immunobiology* (2013) 218:1524–8. doi: 10.1016/j.imbio.2013.05.006

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Alves, Araujo, Bernardes, Mendes, Oliveira and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.